Therapeutics News and Research

RSS

Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma

Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.

24 Sep 2010

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

24 Sep 2010

NYU Langone Medical Center announces presentations at TCT 2010 scientific symposium

Researchers from the Cardiac & Vascular Institute at NYU Langone Medical Center will present at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium on September 21-25, 2010 in Washington, DC.

24 Sep 2010

Preclinical data of novel drug-resistant hypertension therapy presented at TCT 2010

Preclinical data of a novel therapy designed to treat drug-resistant hypertension (high blood pressure) was presented Tuesday, September 21st, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Conference in Washington, DC, by Christopher D. Owens, MD, MSc, Assistant Professor in Residence, Division of Vascular and Endovascular Surgery, University of California, San Francisco.

24 Sep 2010

Scientists uncover alternative source for damage associated with MS

Scientists have uncovered an alternative source for some of the damage associated with multiple sclerosis, an incurable neuroinflammatory disorder. The research, published online by Cell Press on September 23rd in the journal Immunity, reveals a direct interaction between immune cells and neurons that plays a significant role in neuronal injury and may respond to therapeutic intervention.

24 Sep 2010

New data demonstrates safety and efficacy of Resolute drug-eluting stent

Coronary artery disease, a leading cause of death and poor quality of life worldwide, runs the gamut from simple to complex, which complicates the daily practice of interventional cardiology. New clinical data from a second, large international study that enrolled "all comers," regardless of disease complexity and comorbidities, again demonstrated the strong performance of the Resolute drug-eluting stent (DES) from Medtronic, Inc. for patients across this continuum.

24 Sep 2010

FDA designates AMT-080 gene therapy for Duchenne muscular dystrophy

Amsterdam Molecular Therapeutics (AMT) Holding N.V. a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration (FDA) has designated AMT-080, a gene therapy for Duchenne muscular dystrophy (DMD) as an orphan drug.

24 Sep 2010

Belfer Institute, sanofi-aventis collaborate to discover anticancer drugs

Dana-Farber Cancer Institute's Belfer Institute of Applied Cancer Science (Belfer Institute) and sanofi-aventis announced today that they have entered into a collaboration and license option agreement to identify and validate novel oncology targets for further discovery and development by sanofi-aventis of novel therapeutics agents directed to such targets and related biomarkers.

24 Sep 2010

NeoStem signs merger agreement to acquire Progenitor Cell Therapy

NeoStem, Inc. an international biopharmaceutical company with operations in the U.S. and China and Progenitor Cell Therapy, LLC a privately held cell therapy company that serves the cell therapy industry from licensed, state-of-the art cell therapy manufacturing facilities in New Jersey and California today jointly announced the signing of a definitive merger agreement whereby NeoStem will acquire Progenitor Cell Therapy.

24 Sep 2010

Immune-mediated disturbances of neurons contribute to MS: Research

Researchers in Germany have gained new insight into how the immune system causes damage associated with multiple sclerosis (MS), an incurable neuroinflammatory disorder.

24 Sep 2010

Advanced Targeting Systems receives NCI award to advance SP-SAP drug

Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases and for research into the function of biological systems, has been awarded $3 million from the National Cancer Institute (NCI).

24 Sep 2010

Lutonix presents data on Moxy Drug Coated Balloon Catheter at TCT meeting

Lutonix, Inc., headquartered in Minneapolis, MN, today announced six-month data from three separate drug coated balloon studies presented at the TransCatheter Therapeutics (TCT) meeting this week demonstrated the ability of the Moxy Drug Coated Balloon Catheter to inhibit restenosis in both peripheral and coronary arteries.

24 Sep 2010

Zalicus presents synergistic drug data at Targeted Cancer Therapies World Europe 2010 meeting

Zalicus Inc. presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the Targeted Cancer Therapies World Europe 2010 meeting in Zurich on September 23, 2010.

24 Sep 2010

CytomX Therapeutics completes $30 million Series B financing

CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated antibodies, today announced it has completed a $30 million Series B financing.

23 Sep 2010

Use of CYPHER stent in diabetic patients can result in significant cost savings

New analysis presented at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2010) in Washington, DC, indicates that the broad use of CYPHER Sirolimus-eluting coronary stent in patients with diabetes would result in substantial cost savings, as compared to the use of everolimus-eluting stents (EES), paclitaxel-eluting stents (PES), or zotarolimus-eluting stents (ZES).

23 Sep 2010

Athersys presents MultiStem phase I study results at TCT Conference

Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).

23 Sep 2010

Abbott announces positive results of bioresorbable vascular device at TCT conference

Abbott today announced positive nine-month results from the first 45 patients enrolled in the second stage of the ABSORB trial. At nine months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results that remained consistent with the six-month data from the same 45-patient group, with the rate of major adverse cardiac events (MACE) unchanged at 4.4 percent and no reports of blood clots (thromboses).

23 Sep 2010

LWW and Ovid enter collaboration with Joanna Briggs Institute

Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy, has announced an exclusive partnership with the Joanna Briggs Institute (JBI), a recognized global leader in evidence-based healthcare resources based at the University of Adelaide, Australia, as part of an expansion of the nursing, allied health, and medical content delivered to customers of products in the Lippincott Williams & Wilkins (LWW) journals and Ovid brands.

23 Sep 2010

Erasmus Medical Center Professor to present LEADERS trial result at TCT symposium

Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

23 Sep 2010

St. Jude Medical to highlight OCT product platform at TCT meeting

St. Jude Medical, Inc., a global medical device company, will highlight recently launched technology, including its new Optical Coherence Tomography (OCT) product platform, at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C.

23 Sep 2010

Therapeutics News and Research

Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

NYU Langone Medical Center announces presentations at TCT 2010 scientific symposium

Preclinical data of novel drug-resistant hypertension therapy presented at TCT 2010

Scientists uncover alternative source for damage associated with MS

New data demonstrates safety and efficacy of Resolute drug-eluting stent

FDA designates AMT-080 gene therapy for Duchenne muscular dystrophy

Belfer Institute, sanofi-aventis collaborate to discover anticancer drugs

NeoStem signs merger agreement to acquire Progenitor Cell Therapy

Immune-mediated disturbances of neurons contribute to MS: Research

Advanced Targeting Systems receives NCI award to advance SP-SAP drug

Lutonix presents data on Moxy Drug Coated Balloon Catheter at TCT meeting

Zalicus presents synergistic drug data at Targeted Cancer Therapies World Europe 2010 meeting

CytomX Therapeutics completes $30 million Series B financing

Use of CYPHER stent in diabetic patients can result in significant cost savings

Athersys presents MultiStem phase I study results at TCT Conference

Abbott announces positive results of bioresorbable vascular device at TCT conference

LWW and Ovid enter collaboration with Joanna Briggs Institute

Erasmus Medical Center Professor to present LEADERS trial result at TCT symposium

St. Jude Medical to highlight OCT product platform at TCT meeting

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News